EmeritusDX Introduces Advanced 13-Color Flow Cytometry for Hematologic Analysis

IRVINE, Calif., Oct. 6, 2026 /CourierPR/ -- EmeritusDX, a laboratory accredited by the College of American Pathologists (CAP) and certified by the Clinical Laboratory Improvement Amendments (CLIA), has introduced advanced 13-color, 15-parameter flow cytometry to its diagnostic offerings. This new technology aims to enhance the diagnosis, classification, and monitoring of hematologic malignancies and disorders by providing more comprehensive and efficient analysis.

The new flow cytometry system allows for the evaluation of multiple markers simultaneously within a single tube, correlating abnormal marker expression to the same cellular population. This higher-dimensional approach provides greater diagnostic information while reducing the number of tubes required, making it particularly useful for characterizing complex or heterogeneous cell populations. By evaluating lineage, clonality, cell maturity, and the coexpression of abnormal markers, the technology supports comprehensive immunophenotypic characterization and can provide a strong preliminary disease classification after a single run.

The new offering includes advanced multiparameter analysis for comprehensive immunophenotypic characterization, more diagnostic information from fewer tubes, greater characterization of complex and heterogeneous cell populations, earlier preliminary disease classification to help guide targeted downstream testing, and rapid turnaround, with approximately 90% of cases reported the same day they are received. EmeritusDX also offers direct access to board-certified hematopathologists for diagnostic consultation and case discussions, as well as flexible partnership options, including full-service testing and Technical Component Flow Cytometry services.

EmeritusDX's broad range of hematopathology services includes flow cytometry, molecular testing, cytogenetics, fluorescence in situ hybridization (FISH), and hematopathology consultation. The company's commitment to providing physicians with timely, actionable clinical information is reflected in its continued investment in advanced diagnostic technologies.

The addition of 13-color, 15-parameter flow cytometry is part of EmeritusDX's ongoing efforts to support rapid, comprehensive hematologic evaluation. By making better use of patient specimens and providing a more complete picture of complex cell populations, the new technology is expected to enhance the accuracy and efficiency of diagnostic processes.